TradingKey

Más Datos de Exelixis Inc Compañía

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Información de la empresa

Código de la empresaEXEL

Nombre de la empresaExelixis Inc

Fecha de salida a bolsaApr 11, 2000

Fundada en1994

Director ejecutivoDr. Michael M. Morrissey, Ph.D.

Número de empleados1147

Tipo de seguridadOrdinary Share

Fin del año fiscalApr 11

Dirección1851 Harbor Bay Parkway

CiudadALAMEDA

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94502

Teléfono16508377000

Sitio Webhttps://www.exelixis.com/

Código de la empresaEXEL

Fecha de salida a bolsaApr 11, 2000

Fundada en1994

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.37M

+33.08%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.26M

+0.15%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

469.73K

+48.81%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Discovery and Translational Research, Chief Scientific Officer

391.52K

+51.34%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

347.62K

+75.36%

Mr. Jack L. Wyszomierski

Independent Director

337.77K

+2.73%

Dr. Amy C. Peterson, M.D.

Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer

192.16K

+486.28%

Dr. George H. Poste, Ph.D.

Independent Director

150.18K

+1.27%

Dr. Maria C. Freire, Ph.D.

Independent Director

72.17K

+2.67%

Ms. Julie Anne Smith

Independent Director

763.00

-92.92%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.37M

+33.08%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.26M

+0.15%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

469.73K

+48.81%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Discovery and Translational Research, Chief Scientific Officer

391.52K

+51.34%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

347.62K

+75.36%

Mr. Jack L. Wyszomierski

Independent Director

337.77K

+2.73%

Desglose de ingresos

Divisa: USDHora de actualización: dom., 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

CABOMETYX

1.80B

82.92%

License revenues

349.24M

16.10%

COMETRIQ

11.16M

0.51%

Collaboration services revenues

10.06M

0.46%

Por regiónUSD

Nombre

Ganancia

Proporción

U.S

1.82B

84.06%

Europe

318.63M

14.69%

Japan

27.08M

1.25%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

CABOMETYX

1.80B

82.92%

License revenues

349.24M

16.10%

COMETRIQ

11.16M

0.51%

Collaboration services revenues

10.06M

0.46%

Accionista

Hora de actualización: vie., 21 de feb

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

10.66%

BlackRock Institutional Trust Company, N.A.

9.69%

Farallon Capital Management, L.L.C.

8.51%

Renaissance Technologies LLC

5.55%

State Street Global Advisors (US)

4.14%

Other

61.45%

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

10.66%

BlackRock Institutional Trust Company, N.A.

9.69%

Farallon Capital Management, L.L.C.

8.51%

Renaissance Technologies LLC

5.55%

State Street Global Advisors (US)

4.14%

Other

61.45%

Tipo

Accionista

Proporción

Investment Advisor/Hedge Fund

35.97%

Investment Advisor

33.06%

Hedge Fund

18.79%

Pension Fund

2.95%

Individual Investor

2.28%

Research Firm

1.77%

Sovereign Wealth Fund

1.22%

Bank and Trust

0.48%

Family Office

0.10%

Other

3.38%

Participación institucional

Hora de actualización: lun., 20 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

972

265.48M

94.85%

-6.82M

2024Q4

992

262.76M

93.66%

-11.36M

2024Q3

924

259.58M

90.96%

-10.18M

2024Q2

908

255.61M

87.75%

-22.29M

2024Q1

905

264.69M

87.26%

-20.82M

2023Q4

882

270.85M

87.07%

-16.64M

2023Q3

847

278.02M

87.32%

-18.15M

2023Q2

833

285.95M

87.85%

-21.34M

2023Q1

841

294.75M

90.97%

-14.08M

2022Q4

839

295.50M

91.62%

-5.46M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

29.37M

10.49%

+120.47K

+0.41%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

26.71M

9.54%

-308.83K

-1.14%

Dec 31, 2024

Farallon Capital Management, L.L.C.

23.44M

8.37%

--

Mar 05, 2025

Renaissance Technologies LLC

15.30M

5.47%

-64.05K

-0.42%

Dec 31, 2024

State Street Global Advisors (US)

11.41M

4.08%

-31.73K

-0.28%

Dec 31, 2024

LSV Asset Management

8.17M

2.92%

+67.47K

+0.83%

Dec 31, 2024

Fuller & Thaler Asset Management Inc.

7.63M

2.73%

+708.31K

+10.23%

Dec 31, 2024

Geode Capital Management, L.L.C.

5.16M

1.84%

-5.12K

-0.10%

Dec 31, 2024

Dimensional Fund Advisors, L.P.

5.10M

1.82%

-153.57K

-2.92%

Dec 31, 2024

AQR Capital Management, LLC

3.97M

1.42%

+810.86K

+25.69%

Dec 31, 2024

ETFs relacionados

Hora de actualización: dom., 6 de abr

Nombre

Proporción

iShares Genomics Immunology and Healthcare ETF

4.81%

Tema Oncology ETF

4.2%

Alger Russell Innovation ETF

3.77%

First Trust NYSE Arca Biotechnology Index Fund

3.34%

Burney US Factor Rotation ETF

3.31%

Invesco Biotechnology & Genome ETF

2.89%

ERShares Entrepreneurs ETF

2.66%

First Trust Health Care Alphadex Fund

2.51%

Range Cancer Immunotherapy ETF

2.48%

Adaptiv Select ETF

2.04%

iShares Genomics Immunology and Healthcare ETF

Proporción4.81%

Tema Oncology ETF

Proporción4.2%

Alger Russell Innovation ETF

Proporción3.77%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.34%

Burney US Factor Rotation ETF

Proporción3.31%

Invesco Biotechnology & Genome ETF

Proporción2.89%

ERShares Entrepreneurs ETF

Proporción2.66%

First Trust Health Care Alphadex Fund

Proporción2.51%

Range Cancer Immunotherapy ETF

Proporción2.48%

Adaptiv Select ETF

Proporción2.04%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Exelixis Inc

38.090USD

Exelixis Inc

38.090

Descripción general

Compañía